The Helsinki Stock Exchange was quoted 15 minutes after opening with a 0.1 percent decrease at 9,484 points.
In the most traded stocks Nokia had fallen to 0.3 percent to 3.39 euros. Nordea was, on the other hand, down 0.4 percent at 10.52 euros. Nokian Tires the course had fallen by 3.6 percent.
Drug developer Pharaoh reported phase 2 results from an ongoing trial of BEXMAB in patients with myelodysplastic syndrome (MDS) unresponsive to hypomethylating agents (HMA), also known as relapsed/resistant MDS.
Preliminary phase 2 results of the BEXMAB trial have already shown a high objective response rate of 79 percent (11/14) in MDS patients treated with the combination of bexmarilimab and azacitidine who did not respond to HMA.
Now a total of 20 corresponding patients can be evaluated with this new combination. The treatment has been well tolerated, without dose-limiting toxicity. The objective response is 80 percent (16/20).
The BEXMAB study continues to recruit patients as planned, with the next study data readout expected in late Q1 2025.
The share was quoted with a 7.3 percent increase at 2.07 euros.
Premises implementer Tekova plans to list on the stock exchange’s First North list.
The planned IPO would be carried out in December as a technical IPO, i.e. no share issue or sale will be organized in connection with it. Acting CEO Jaakko Heikkilän at this stage, the motive for the listing is to improve the company’s recognition and credibility.
The company specializes in the construction of business, office, logistics, production and sports facilities. In total, the company has implemented about a hundred projects.
Konecranes long time customer Transped S.p.A. has ordered a sixth generation mobile Gottwald harbor crane from Konecranes. With the new crane, the company aims to increase its handling capacity and efficiency at the port of Venezia-Marghera in Italy.
The order was booked in the last quarter of 2024 and will be delivered in the second quarter of 2025.
The course had fallen by 0.6 percent to 62.95 euros.